VTVT vTv Therapeutics Inc.

Margins & Returns

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.